An investigation on behalf of investors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) shares over potential securities laws violations by Sarepta Therapeutics, Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) concerning whether a series of statements by Sarepta Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Cambridge, MA based Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. On August 19, 2019, Sarepta Therapeutics, Inc. announced receipt of a Complete Response Letter (CRL) from the U.S. Food & Drug Administration regarding the Companys New Drug Application seeking accelerated approval of golodirsen injection for the treatment of Duchenne muscular dystrophy. Sarepta disclosed that [t]he CRL generally cites two concerns: the risk of infections related to intravenous infusion ports and renal toxicity seen in pre-clinical models of golodirsen and observed following administration of other antisense oligonucleotides. Shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) declined to as low as $90.24 per share on August 22, 2019.